Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Insmed Inc INSM

Healthcare Biotechnology
Insmed Incorporated is a global biopharmaceutical company. The Company's first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs... see more

Recent & Breaking News (NDAQ:INSM)

Insmed to Present at the 38th Annual J.P. Morgan Healthcare Conference

PR Newswire January 9, 2020

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire January 3, 2020

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire December 3, 2019

Insmed to Present at Two December Conferences

PR Newswire November 26, 2019

Insmed Appoints Dr. Clarissa Desjardins to its Board of Directors and Names Roger Adsett Chief Operating Officer

PR Newswire November 14, 2019

Insmed to Present at Two November Conferences

PR Newswire November 5, 2019

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire November 4, 2019

Insmed Reports Third Quarter 2019 Financial Results and Provides Business Update

PR Newswire October 30, 2019

Insmed to Host Third Quarter 2019 Financial Results Conference Call on Wednesday, October 30, 2019

PR Newswire October 23, 2019

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire October 7, 2019

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire September 5, 2019

Insmed to Present at Two September Conferences

PR Newswire September 3, 2019

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire August 2, 2019

Insmed Reports Second Quarter 2019 Financial Results and Provides Business Update

PR Newswire August 1, 2019

Insmed to Host Second Quarter 2019 Financial Results Conference Call on Thursday, August 1, 2019

PR Newswire July 25, 2019

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire July 2, 2019

Insmed Announces Closing of Public Offering of Common Stock

PR Newswire June 26, 2019

Insmed to Present at the Goldman Sachs 40th Annual Global Healthcare Conference

PR Newswire June 6, 2019

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire June 4, 2019

Insmed Announces Closing of Public Offering of Common Stock

PR Newswire May 24, 2019
USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse
Later
Participate
Not interested